MMP9 and central nervous system cancer: Recent studies confirmed that IDH1 mutation is associated with better prognosis in patients with glioma by inducing cell cycle arrest in G1 phase, inhibiting cell proliferation, and reducing invasion ability, by reducing the levels of matrix metalloproteinases MMP2 and MMP9 [25].